DISEASE MODIFYING ANTIRHEUMATIC DRUG (DMARD) MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

Disease-modifying anti-rheumatic drugs (DMARDs) can treat the underlying cause of condition and reduce inflammation. They are given to people with autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis and others. These are conditions where the immune system, which normally fights infection, attacks the body’s own healthy tissues. DMARDs can improve symptoms such as pain, stiffness and swelling, but they may take a few weeks or even months to fully take effect. There are different types of DMARDs, and they work in slightly different ways. The three main types are: synthetic (sDMARD), targeted synthetic DMARDs, biological DMARDs (bDMARD) and others

Market Dynamics

Key players operating in the global disease-modifying anti-rheumatic drugs (DMARDs) market are focusing on increasing product launches and product approvals which is expected to drive the market growth during the forecast period. For instance, in January 2018, Hetero, one of the leading generic pharmaceutical companies launched its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘Mabura’ in India.  Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF). It is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Moreover, in September 2020, Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation announced that the U.S. Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.

 Key features of the study:

• This report provides an in-depth analysis of the global disease-modifying anti-rheumatic drugs (DMARDs)  market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global disease-modifying anti-rheumatic drugs (DMARDs)  market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Sanofi.,  Pfizer,  F. Hoffman-La Roche AG,  Johnson & Johnson,  AbbVie Inc., Eli Lilly & Company,  Amgen Inc.,  Swedish Orphan Biovitrum AB,  Bristol-Myers Squibb Company,  UCB S.A.,  Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global disease-modifying anti-rheumatic drugs (DMARDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global disease-modifying anti-rheumatic drugs (DMARDs) market

Detailed Segmentation:

• Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Drug Type:
  • Synthetic (sDMARD)
    • Conventional synthetic (csDMARDs)
      • Methotrexate
      • Sulfasalazine
      • Leflunomide
      • Hydroxychloroquine
      • Gold Salts
  • Targeted synthetic DMARDs (tsDMARDs)
  • Biological DMARDs (bDMARD)
    • Original DMARDs (boDMARDs)
    • Biosimilar DMARDs (bsDMARDs)
    • Primary
    • Secondary
    • Tertiary
  • Others
• Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Route of Administration  :
  • Oral
  • Parenteral
  • Others
• Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Indication :
  • Rheumatoid Arthritis
    • Ankylosing Spondylitis
    • Psoriatic Arthritis
    • Systemic Lupus Erythematosus
    • Others
• Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Distribution Channel  :
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Sanofi *
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer.
  • F. Hoffman-La Roche AG
  •  Johnson & Johnson
  • AbbVie Inc.
  • Eli Lilly & Company
  • Amgen Inc.
  • Swedish Orphan Biovitrum AB
  • Bristol-Myers Squibb Company
  • UCB S.A.
  • Gilead Sciences, Inc.
  • Cumberland Pharmaceuticals Inc.

“*” marked represents similar segmentation in other categories in the respective section.